AOD-9604

Blood Sugar Regulation

The C-terminal region of hGH is primarily responsible for the protein's hypoglycemic effects. Testing of at least six different fragments from this region identified Fragment 176-191 as the most effective synthetic derivative for lowering blood sugar, an effect mediated through sustained increases in plasma insulin levels (Ng & Bornstein, 1978). These findings have generated interest in the peptide as a potential treatment for prediabetes and type 2 diabetes.

Cartilage Regeneration

A 2015 study demonstrated that Fragment 176-191 potentiates the effects of hyaluronic acid (HA) in promoting cartilage regeneration. In a rabbit osteoarthritis model, weekly injections of Fragment 176-191 increased cartilage growth markers, with co-administration with HA producing even more substantial effects. The peptide also reduced disability associated with osteoarthritis, suggesting potential therapeutic applications that may reduce the need for surgical intervention (Kwon & Park, 2015).

Fat Burning and Weight Loss

Fragment 176-191 earned its "lipolytic fragment" nickname through robust fat-burning effects in animal models. The mechanism is mediated by increased ADRB3 production -- mice genetically engineered to lack ADRB3 do not respond to the lipolytic effects of either hGH or Fragment 176-191 (Heffernan et al., 2001). ADRB3 agonism drives fat oxidation in adipose tissue and thermogenesis in skeletal muscle (Ferrer-Lorente et al., 2005).

Studies demonstrate that Fragment 176-191 produces a nearly 50% reduction in weight gain in obese animals over a three-week course (Ng et al., 2000). Notably, weight loss effects were observed only in obese mice; lean animals maintained normal body weight, suggesting secondary regulatory pathways override ADRB3 function when body weight is at or near ideal (Heffernan et al., 2001). These findings reveal opportunities for additional research into energy homeostasis regulation.

Bone Regeneration

Research has also explored AOD-9604's effects on bone metabolism. Studies in animal models suggest that AOD-9604 can stimulate osteoblast differentiation and promote bone formation, potentially complementing its cartilage-protective effects in musculoskeletal applications. This bone-anabolic activity, combined with its chondroprotective properties, positions AOD-9604 as a candidate for comprehensive joint repair strategies.

Ongoing & Future Research

AOD-9604 research continues across multiple therapeutic areas:

• Intra-articular Injection for Knee Osteoarthritis: Multiple clinical programs are evaluating AOD-9604 as an intra-articular injection for symptomatic knee OA. These studies build on preclinical cartilage regeneration data and aim to demonstrate disease-modifying effects (structural improvement on MRI) in addition to symptomatic relief. Dose-ranging and safety studies are underway to establish optimal injection volumes and treatment intervals.

• Oral Formulation Development: Following the successful oral dosing in Phase 2b obesity trials, ongoing pharmaceutical development seeks to optimize oral formulations of AOD-9604 for both metabolic and musculoskeletal indications. Enteric coating and sustained-release technologies are being explored to improve bioavailability and reduce dosing frequency compared to the original immediate-release formulation.

• Combination Approaches: Research groups are investigating AOD-9604 in combination with hyaluronic acid and platelet-rich plasma (PRP) for enhanced joint regeneration. These multi-modal protocols aim to address the inflammatory, structural, and biomechanical components of OA simultaneously.

• Bone Regeneration Applications: Based on early findings showing osteoblast stimulation, studies are exploring AOD-9604 for delayed fracture healing and osteoporotic bone loss, potentially expanding its musculoskeletal applications beyond cartilage to bone repair.

Fat Metabolism and Obesity

The foundational research for AOD-9604 demonstrated its ability to reduce body fat in obese animal models without the side effects of full-length GH administration. In a study by Ng et al., obese Zucker rats treated with AOD-9604 showed significant reductions in body weight and adipose tissue mass compared to controls, without changes in food intake, IGF-1 levels, or glucose metabolism Ng et al. (2000). A Phase 2b randomized, double-blind, placebo-controlled trial in 300 obese subjects demonstrated that oral AOD-9604 (1 mg/day) produced statistically significant weight loss compared to placebo over 12 weeks, with a favorable safety profile and no adverse effects on glucose or IGF-1 Stier et al. (2013).

Osteoarthritis and Cartilage Repair

AOD-9604 has shown promising results in osteoarthritis (OA) research. In vitro studies demonstrate that AOD-9604 stimulates proteoglycan and collagen type II production in human articular chondrocytes while inhibiting catabolic enzymes (MMP-1, MMP-3, MMP-13) that degrade cartilage matrix. Animal models of OA treated with intra-articular AOD-9604 have shown improvements in cartilage integrity and reduced joint degeneration. These findings led to ongoing clinical investigation of AOD-9604 as an intra-articular injection for knee osteoarthritis Kwon et al. (2012).

Safety and Regulatory Status

AOD-9604 achieved a notable regulatory milestone when the FDA granted it GRAS (Generally Recognized As Safe) status in 2014 for use as a food substance. This designation was based on extensive toxicology data demonstrating no genotoxicity, reproductive toxicity, or carcinogenicity in preclinical studies, as well as favorable safety data from multiple clinical trials involving over 900 human subjects Thompson et al. (2004).

Comparison to Related Compounds

AOD-9604 vs HGH Fragment 176-191: AOD-9604 is a modified version of Fragment 176-191 with the addition of a tyrosine (Tyr) residue. The sequences are nearly identical -- Fragment 176-191 corresponds to the native hGH sequence, while AOD-9604 adds Tyr to enhance stability and provide a disulfide bridge anchor point. Both peptides share the same ADRB3-mediated mechanism and neither elevates IGF-1. AOD-9604 has substantially more clinical data, including completed Phase 2b trials and FDA GRAS determination Ng et al. (2000) — PMID: 11146367.

AOD-9604 vs Full-length GH: Growth hormone produces lipolytic effects through the same C-terminal region that AOD-9604 is derived from, but full-length GH also activates the somatotropic axis (IGF-1 elevation), promotes cell proliferation, causes insulin resistance, and can produce acromegaly-like symptoms at supraphysiological doses. AOD-9604 isolates the lipolytic activity without these systemic effects Heffernan et al. (2001) — PMID: 11713213.

AOD-9604 vs Tirzepatide/Semaglutide: The GLP-1 receptor agonists produce dramatically greater weight loss (15-22% with tirzepatide vs ~2-3 kg with AOD-9604) through centrally-mediated appetite suppression, delayed gastric emptying, and metabolic effects. However, AOD-9604 has a distinct mechanism (ADRB3-mediated direct lipolysis), minimal side effects (no GI effects), and additional musculoskeletal benefits that GLP-1 agonists lack. AOD-9604 may be better positioned as a complementary agent for metabolic health and joint repair rather than as a primary obesity monotherapy DOI: 10.1056/NEJMoa2206038.

Clinical Research Protocols

Fragment 176-191 has been evaluated in multiple Phase 2b clinical trials using both intravenous and oral routes of administration. A comprehensive meta-analysis by Stier et al. reviewed six randomized, double-blind, placebo-controlled trials encompassing both routes. IV protocols typically used single-dose or short-course administration for pharmacokinetic characterization and acute metabolic endpoint assessment (glucose, insulin, free fatty acids). Oral protocols used daily dosing over 12-week periods with body weight as the primary endpoint and metabolic safety parameters as secondary endpoints Stier et al. (2013) — DOI: 10.14740/jem116w.

In obesity study protocols, Fragment 176-191 was administered to overweight and obese adults (BMI 28-40) with efficacy assessed by change in body weight, waist circumference, and body composition via DEXA. Metabolic safety monitoring included fasting glucose, oral glucose tolerance tests, insulin sensitivity (HOMA-IR), IGF-1 levels, and lipid panels. The consistent finding across studies was fat loss in obese subjects without changes in any metabolic safety parameter Ng et al. (2000) — PMID: 11146368.

Cartilage regeneration protocols in rabbit models used weekly intra-articular injections of Fragment 176-191, alone or co-administered with hyaluronic acid. Efficacy was assessed via histological scoring (Mankin score), cartilage thickness measurement, proteoglycan and type II collagen immunostaining, and functional disability scoring. The rabbit OA model was induced surgically via anterior cruciate ligament transection (ACLT), with treatment beginning 4 weeks post-surgery Kwon & Park (2015) — PMID: 26275692.